Experimental Donor-Cell therapy takes aim at tough autoimmune diseases

NCT ID NCT06294236

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the disease. Participants receive the cells after a short chemotherapy course to prepare their bodies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SC291 (a type of CAR T cell therapy made from donor cells)
What this could lead to
If it works, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 7 participants, so safety and effectiveness are not yet proven. There may be serious side effects, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Swedish Medical Center

    Seattle, Washington, 98122, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.